Shanghai Junshi Bioscience Co., Ltd.

This trial is testing whether an experimental drug called JS015, when combined with standard chemotherapy or immunotherapy, is safe and effective for people with advanced solid tumors that have not responded to prior treatment. The study includes patients with certain cancers lik…

This trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation and have stopped responding to TKI targeted therapy. About 440 participants will be…

This trial is testing whether combining two drugs—toripalimab, an immunotherapy, and cetuximab, a targeted therapy—can shrink tumors in people with advanced head and neck squamous cell cancer. The study includes patients whose cancer has returned or spread after initial treatment…

This phase 3 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with stage II-III non-small cell lung cancer. Participants receive either toripalimab plus chemotherapy or a placebo plus chemotherap…

This phase 2 trial tests an experimental drug called JS005 in adults with active ankylosing spondylitis, a type of arthritis that mainly affects the spine. Participants receive different doses of JS005 or a placebo as a shot under the skin. The study measures whether JS005 improv…

This early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…

This phase 2 trial tests an experimental drug called JS005 in adults with active ankylosing spondylitis, a type of arthritis that mainly affects the spine. JS005 is a lab-made antibody that blocks IL-17A, a protein involved in inflammation. The study compares JS005 injections to …

This Phase 1 trial evaluates the safety, tolerability, and how the body processes a single dose of JS010 injection in healthy adults aged 18 to 45. Participants receive one of six dose levels or a placebo to assess side effects and drug levels in the blood. The goal is to gather …

This phase 3 trial compares a combination of two drugs—toripalimab (an immunotherapy) and bevacizumab (an anti-angiogenic agent)—against the standard drug sorafenib as the first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolls a…

This early-phase trial tests an experimental drug called JS006, either by itself or combined with another drug (toripalimab), in people with advanced tumors who have no standard treatment options left. The goal is to see if the combination is safe and tolerable, and to find the b…

This phase 2 trial investigates whether combining toripalimab (an immunotherapy) with bevacizumab (a drug that cuts off tumor blood supply) can safely shrink advanced liver cancer when used as the first treatment. About 50 to 60 adults with intermediate or late-stage liver cancer…

This early-stage trial tests an experimental antibody called JS004, which targets a protein on immune cells called BTLA, to see if it can help the immune system fight advanced solid tumors like melanoma, kidney cancer, and bladder cancer. The study includes JS004 alone or combine…

This phase I study is testing a subcutaneous (under the skin) injection of toripalimab, an immunotherapy drug, for people with advanced nasopharyngeal carcinoma. The trial compares the new injection to the standard intravenous (IV) version, looking at safety, tolerability, and ho…

This phase 3 trial tested whether adding the immunotherapy drug toripalimab to standard chemotherapy (nab-paclitaxel) helps people with metastatic or recurrent triple-negative breast cancer live longer without their cancer growing. The study included 531 participants and compared…

This Phase 3 trial tested a new drug called JS005 in 747 adults with moderate-to-severe plaque psoriasis. JS005 is an antibody that blocks IL-17A, a protein that drives inflammation in psoriasis. The study compared JS005 to a placebo to see if it could improve skin clearance, mea…

This study tested a new experimental drug called JS004, combined with another immunotherapy (toripalimab) and standard chemotherapy, in 119 people with advanced lung cancer. The goal was to see if the combination is safe and might help shrink tumors. The trial has finished, but r…

This phase 3 trial tested whether combining the immunotherapy toripalimab with the targeted drug axitinib works better than the standard drug sunitinib for people with advanced kidney cancer that cannot be removed by surgery. Over 400 participants received either the combination …

This phase 3 trial tested whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with recurrent or metastatic nasopharyngeal cancer live longer without their disease getting worse. About 289 adults with advanced cancer that could not be treated wi…

This early-stage trial is testing whether a single dose of an experimental antibody called JS005 is safe and well-tolerated in healthy volunteers. The antibody targets IL-17A, a protein that drives inflammation, and could one day help treat inflammatory diseases. The study will a…

This study tested whether two different injection devices (a pre-filled syringe and an automatic injector) deliver the same amount of the drug JS005 into the body. It involved 272 healthy adults who received a single injection and were followed for 85 days. The goal was to see if…